Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin‐naive adults with suboptimally controlled type 2 diabetes
Authors' conclusion
In people with T2D suboptimally controlled on ≥2 OADs ± GLP-1 RA, 16 weeks' treatment with iGlarLixi resulted in a trend of improvement in treatment satisfaction.
Study context
- Population
- Insulin-naive adults with suboptimally controlled T2D (HbA1c 9%-13% on ≥2 OADs ± GLP-1 RA)107 completed DM-SAT at Week 16
- Participants
- 124 adults
- Comparison
- iGlarLixi, baseline vs Week 16
- iGlarLixin = 124
- Primary endpoint
- TIR (primary endpoint of Soli-CGM)
- Follow-up
- Week 16
Methodological details16-week, multicentre, interventional, open-label, phase 4, blinded continuous glucose monitoring (CGM)
- 16-week
- Multicentre
- Interventional
- Open-label
- Phase 4
- Blinded CGM
Primary result
As reported in the abstract
DM-SAT mean overall score
Mean overall score at baseline
0.59
Mean overall score at Week 16
0.78
Mean overall score increase
0.18
Further findings
Association of time in range (TIR) improvement with overall treatment satisfaction improvement
- Positive but weak trend of association (mean r)
- 0.14
TIR (primary endpoint of Soli-CGM) · Week 16
- TIR at baseline
- 26.4%
- TIR at Week 16
- 52.7%
Original publication
Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin‐naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. Published 14 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →